{"entity":{"id":"inrg-staging","kind":"term","name":"INRG staging and risk groups","aka":["INRGSS","INRG stage","INRG risk group","INRG classification","INPC","INPC histology","International Neuroblastoma Pathology Classification","Shimada classification","INSS","International Neuroblastoma Staging System","image-defined risk factors","IDRF","stage L1","stage L2","stage M","stage MS"],"tldr":"INRG staging is the international system that sorts neuroblastoma into four risk groups, from the lowest (often observed, sometimes regressing on its own) to high risk (about half of patients), using age under 18 months, spread, MYCN amplification, 11q status, ploidy and histology.","summary":"International Neuroblastoma Risk Group (2009): stages L1/L2 (localised, by image-defined risk factors), M (metastatic), MS (infant metastatic to skin/liver/marrow). Risk groups combine stage, age (<18 months), MYCN amplification, 11q aberration, ploidy and histology. Roughly 50% of patients are high risk; very-low-risk L1/MS may be observed and regress spontaneously.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Neuroblastoma#Staging","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Neuroblastoma#Staging"}],"tags":[],"related":[],"cancers":["neuroblastoma","neuroblastoma-low-risk","neuroblastoma-intermediate-risk","neuroblastoma-high-risk"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Clinical"},"route":"/terms/inrg-staging/","neighbours":{"cancer":[{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/"},{"id":"neuroblastoma-intermediate-risk","kind":"cancer","name":"Intermediate-risk neuroblastoma","route":"/cancers/neuroblastoma-intermediate-risk/"},{"id":"neuroblastoma-low-risk","kind":"cancer","name":"Low-risk neuroblastoma (INRG very low and low risk, including stage MS)","route":"/cancers/neuroblastoma-low-risk/"},{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"}],"person":[{"id":"susan-cohn","kind":"person","name":"Susan L. Cohn","route":"/people/susan-cohn/"}],"bottleneck":[{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/"}],"term":[{"id":"curie-siopen-score","kind":"term","name":"MIBG Curie and SIOPEN scores","route":"/terms/curie-siopen-score/"},{"id":"segmental-chromosomal-aberrations","kind":"term","name":"Segmental chromosomal aberrations and ploidy (neuroblastoma)","route":"/terms/segmental-chromosomal-aberrations/"},{"id":"urinary-catecholamines","kind":"term","name":"Urinary catecholamine metabolites (VMA and HVA)","route":"/terms/urinary-catecholamines/"}]}}